Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: Results of the randomized placebo-controlled GHSG HD15EPO trial

Journal of Clinical Oncology

Volumn 28, Issue 13, 2010, Pages 2239-2245

  Engert, Andreas ^a   Josting, Andreas ^a   Haverkamp, Heinz ^a   Villalobos, Matthias ^a   Lohri, Andreas ^a   Sökler, Martin ^a   Zijlstra, Josée ^a   Sturm, Isrid ^a   Topp, Max S ^a   Rank, Andreas ^a   Zenz, Thorsten ^a   Vogelhuber, Martin ^a   Nogova, Lucia ^a   Borchmann, Peter ^a   Fuchs, Michael ^a   Flechtner, Hans Henning ^a   Diehl, Volker ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PLACEBO; PREDNISONE; PROCARBAZINE; RECOMBINANT ERYTHROPOIETIN; VINCRISTINE; ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; BEACOPP PROTOCOL;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HODGKIN DISEASE; HUMAN; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TREATMENT FAILURE; ADOLESCENT; BLOOD; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GERMANY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOUBLE-BLIND METHOD; DOXORUBICIN; EPOETIN ALFA; ERYTHROCYTE TRANSFUSION; ETOPOSIDE; FATIGUE; FEMALE; GERMANY; HEMATINICS; HODGKIN DISEASE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROCARBAZINE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 77952306234     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.1835     Document Type: Article

References (32)

1. Groopman JE, Itri LM: Chemotherapy-nduced anemia in adults: Incidence and treatment. J Natl Cancer Inst 91:1616-1634, 1999 (Pubitemid 29479929)
2. Cascinu S, Fedeli A, Del Ferro E, et al: Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo. J Clin Oncol 12:1058-1062, 1994 (Pubitemid 24145337)
3. Cazzola M, Messinger D, Battistel V, et al: Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response. Blood 86:4446-4453, 1995
4. Osterborg A, Boogaerts MA, Cimino R, et al: Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin lymphoma: A randomized multicenter study. Blood 87:2675-2682, 1996 (Pubitemid 26102216)
5. Littlewood TJ, Bajetta E, Nortier JW, et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874, 2001 (Pubitemid 32538196)
6. Henke M, Laszig R, Ruebe C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomized, double-blind, placebo-controlled trial. Lancet 362:1255-1260, 2003 (Pubitemid 37324251)
7. Leyland-Jones B: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459-460, 2003
8. Smith RE, Tchekmedyian NS, Chan D, et al: A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 88:1851-1858, 2003
9. Overgaard J, Hoff C, Sand Hansen A, et al: Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients primary squamous cell carcinoma of the head and neck: The Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. Eur J Cancer 5:6LB, 2007 (suppl; abstr)
10. Brower V: ESAs further restricted, but debate continues. J Natl Cancer Inst 100:1344-1351, 2008
11. Amgen: Aranesp (darbepoetin alfa) package insert. Thousand Oaks, CA, Amgen, 2008
12. Ortho Biotech Products: L.P. PROCRIT (epoetin alfa) package insert. Raritan, NJ, Ortho Biotech, 2008
13. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
14. Josting A, Franklin J, May M, et al: New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin Lymphoma Study Group. J Clin Oncol 20:221-230, 2002 (Pubitemid 34032615)
15. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003 (Pubitemid 36682817)
16. Engel C, Loeffler M, Schmitz S, et al: Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. Ann Oncol 11:1105-1114, 2000
17. Sieber M, Bredenfeld H, Josting A, et al: Fourteen-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: Results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:1734-1739, 2003 (Pubitemid 46638585)
18. Kobe C, Dietlein M, Franklin J, et al: Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112:3989-3994, 2008
19. Flechtner H, Rueffer JU, Henry-Amar M, et al: Quality of life assessment in Hodgkin's disease: A new comprehensive approach - First experiences from the EORTC/GELA and GHSG trials. Ann Oncol 9:147-154, 1998 (suppl 5)
20. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993 (Pubitemid 23073154)
21. Smets EMA, Garsson B, Bonke B, et al: The Multidimensional Fatigue Inventory (MFI): Psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39:315-325, 1995
22. Wassmer G, Eisebitt R: ADDPLAN Adaptive Designs-Plans and Analyses User's Guide, Release 4. Cologne, Germany, ADDPLAN, 2007
23. Tsiatis AA, Rosner GL, Metha C: Exact confidence intervals following a group sequential test. Biometrics 40:797-803, 1984
24. Schwarz R, Hinz A: Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 37:1345-1351, 2001 (Pubitemid 32588744)
25. Boogaerts M, Coiffier B, Kainz C, et al: Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 88:988-995, 2003 (Pubitemid 36560764)
26. Razzouk M, Hord J, Hockenberry M, et al: Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. J Clin Oncol 24:3583-3589, 2006 (Pubitemid 46630530)
27. Bohlius J, Schmidlin K, Brillant C, et al: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomized trials. Lancet 373:1532-1542, 2009
28. Sinclair AM, Rogers N, Busse L, et al: Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br J Cancer 98:1059-1067, 2008 (Pubitemid 351399799)
29. Arcasoy MO: Erythropoiesis-stimulating agent use in cancer: Preclinical and clinical perspectives. Clin Cancer Res 14:4685-4690, 2008
30. Bohlius J, Wilson J, Seidenfeld J, et al: Recombinant human erythropoietins and cancer patients: Updated metaanalysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708-714, 2006 (Pubitemid 43821788)
31. Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998 (Pubitemid 28385655)
32. Corwin HL, Gettinger A, Fabian TC, et al: Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 357:965-976, 2007